Incyte Stock Forecast, Price & News

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Incyte stock.
View analyst ratings for Incyte or view top-rated stocks.

Wall Street analysts have given Incyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Incyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Incyte.

Incyte Co. (NASDAQ:INCY) issued its earnings results on Monday, February, 8th. The biopharmaceutical company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.30. The biopharmaceutical company had revenue of $788.50 million for the quarter, compared to the consensus estimate of $654.08 million. Incyte had a negative trailing twelve-month return on equity of 13.66% and a negative net margin of 13.62%. Incyte's revenue for the quarter was up 36.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.65 EPS.
View Incyte's earnings history.

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INCY stock has increased by 11.6% and is now trading at $80.26.
View which stocks have been most impacted by COVID-19.

20 Wall Street analysts have issued 12-month price objectives for Incyte's stock. Their forecasts range from $70.00 to $124.00. On average, they expect Incyte's stock price to reach $102.93 in the next twelve months. This suggests a possible upside of 28.2% from the stock's current price.
View analysts' price targets for Incyte or view top-rated stocks among Wall Street analysts.

22 employees have rated Incyte CEO Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among Incyte's employees.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and United Therapeutics (UTHR).
View all of INCY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (14.83%), Baker BROS. Advisors LP (14.56%), BlackRock Inc. (8.13%), Renaissance Technologies LLC (2.69%), Dodge & Cox (1.49%) and UBS Asset Management Americas Inc. (1.11%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including Caisse DE Depot ET Placement DU Quebec, Wells Fargo & Company MN, Renaissance Technologies LLC, Alliancebernstein L.P., First Trust Advisors LP, Frontier Capital Management Co. LLC, Northern Trust Corp, and Shikiar Asset Management Inc.. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Paul Trower, Paula J Swain, Steven H Stein, and Yao Wenqing.
View insider buying and selling activity for Incyte or view top insider-selling stocks.

INCY stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Price T Rowe Associates Inc. MD, BlackRock Inc., Assenagon Asset Management S.A., Canada Pension Plan Investment Board, Candriam Luxembourg S.C.A., Nuveen Asset Management LLC, and Morgan Stanley. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Herve Hoppenot.
View insider buying and selling activity for Incyte or or view top insider-buying stocks.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INCY stock can currently be purchased for approximately $80.26.

Incyte has a market capitalization of $17.64 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis.

Incyte employs 1,773 workers across the globe.

Incyte was founded in 1991.

The official website for Incyte is www.incyte.com.

Incyte is headquartered at 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]